Cost-effectiveness of CDK4/6 inhibitors in the first-line treatment of HR+/HER2-metastatic breast cancer in postmenopausal women in Panama

被引：0
|
作者：
Castillo-Fernandez, Omar O.
Lim, Maria
Montano, Lilian
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 05期
关键词：
D O I：
10.1158/1538-7445.SABCS22-P6-05-35
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P6-05-35
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Health care resource utilization and costs of Medicare-enrolled patients with HR+/HER2-metastatic breast cancer treated with a CDK4/6i in the first-line setting
    Behan, Emma
    Veenstra, David L.
    Bansal, Aasthaa
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2025, 31 (01): : 6 - 14
  • [42] Analyzing the changes in the HR+/HER2-metastatic breast cancer (mBC) landscape since the arrival of CDK4/6 inhibitors with machine learning and visual analytics
    Meade, D.
    Alford, S. Hensley
    Mahatma, S.
    Malangone-Monaco, E.
    Boulanger, L.
    Tkacz, J.
    Turner, S. J.
    Chen, S.
    Manson, S.
    Mejia, S.
    Buleje, I.
    Madan, P.
    Kim, G.
    Fowler, R.
    Basar, A.
    CANCER RESEARCH, 2019, 79 (04)
  • [43] CDK4/6 inhibitors combined with fulvestrant for HR+/HER2- advanced breast cancer
    Zhang, Jie
    Hao, Chunfang
    TRANSLATIONAL BREAST CANCER RESEARCH, 2022, 3
  • [44] Treatment patterns and barriers involving the use of CDK4/6 inhibitors for women with HR+, HER2-breast cancer.
    Tolaney, Sara M.
    O'Shaughnessy, Joyce
    Ackbarali, Tariqa
    Crawford, Rebecca
    Carter, Jeffrey D.
    Greene, Laurence
    Sapir, Tamar
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (27)
  • [45] COST-EFFECTIVENESS ANALYSIS OF RIBOCICLIB VERSUS ABEMACICLIB IN THE FIRST-LINE (1L) TREATMENT OF POSTMENOPAUSAL WOMEN WITH HR+/HER2-ADVANCED BREAST CANCER (ABC)
    Cameron, D.
    Sharma, V.
    Biswas, C.
    Clarke, C.
    Chandiwana, D.
    Pathak, P.
    VALUE IN HEALTH, 2022, 25 (12) : S126 - S126
  • [46] Comparative cost-effectiveness analysis of CDK4/6 inhibitors in the first-line treatment of HR-positive and HER2-negative advanced breast cancer: a Markov's model-based evaluation
    Elazzazy, Shereen
    Al-Ziftawi, Nour Hisham
    Mohamed Ibrahim, Mohamed Izham
    Bujassoum, Salha
    Hamad, Anas
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [47] Abemaciclib: a CDK4/6 inhibitor for the treatment of HR+/HER2-advanced breast cancer
    Corona, Silvia Paola
    Generali, Daniele
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2018, 12 : 321 - 330
  • [48] Clinical and economic outcomes by first-line treatment among women with HR+/HER2-metastatic breast cancer in a large US health plan database
    Burton, Tanya
    Byfield, Stacey DaCosta
    Smith, Gregory L.
    Zanotti, Giovanni
    Bell, Timothy J.
    Perkins, Julia J.
    Horblyuk, Ruslan
    Teitelbaum, April
    CURRENT MEDICAL RESEARCH AND OPINION, 2016, 32 (08) : 1417 - 1423
  • [49] Optimizing CDK4/6 inhibitors in advanced HR+/HER2-breast cancer: A personalized approach
    Fontanella, Caterina
    Giorgi, Carlo Alberto
    Russo, Stefania
    Angelini, Silvia
    Nicolardi, Linda
    Giarratano, Tommaso
    Frezzini, Simona
    Pestrin, Marta
    Palleschi, Dario
    Bolzonello, Silvia
    Parolin, Veronica
    Haspinger, Eva R.
    De Rossi, Costanza
    Greco, Filippo
    Gerratana, Lorenzo
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2022, 180
  • [50] Efficacy and Safety of CDK4/6 Inhibitors: A Focus on HR+/HER2-Early Breast Cancer
    Klocker, Eva Valentina
    Egle, Daniel
    Bartsch, Rupert
    Rinnerthaler, Gabriel
    Gnant, Michael
    DRUGS, 2025, 85 (02) : 149 - 169
12345